Article

Cole National sells Pearle Europe shares

Milan, Italy—After acquiring Cole National Corp. in October, Luxottica Group SpA says its new subsidiary has sold all of its shares in Pearle Europe BV to HAL Holding NV for about $191 million.

Milan, Italy-After acquiring Cole National Corp. in October, Luxottica Group SpA says its new subsidiary has sold all of its shares in Pearle Europe BV to HAL Holding NV for about $191 million.

Luxottica officials said the sale was required by the Articles of Association of Pearle Europe in light of the acquisition. HAL owned about 19% of Cole National; the deal allows the Dutch investment company to increase its ownership of Pearle Europe to about 99%.

Pearle Europe operates more than 1,000 outlets in about 11 European countries.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
Wendy Lee, MD, MS, at Controversies in Modern Eye Care 2025.
© 2025 MJH Life Sciences

All rights reserved.